Magrolimab from Gilead, as the first CD47 antibody to enter clinical trials, exhibited effective antitumor activity against hematologic malignancies (e.g., acute myeloid leukemia, AML; higher-risk myelodysplastic syndrome, MDS) and solid tumors. This evidence concerns the gene CD47 and myelodysplastic syndrome.